In a landmark development for Bhutan's healthcare sector, Azista Bhutan Healthcare Limited (ABHL) has firmly established itself as a beacon of innovation and commitment. With the launch of a fully-fledged pharmaceutical manufacturing plant at the sprawling 3.5-acre Motanga Industrial Park, ABHL is set to transform the nation's pharmaceutical landscape.
ABHL, a joint venture between Azista Industries Pvt. Ltd. from Hyderabad, India, and Druk Holding and Investments Ltd (DHI), embodies a vision deeply rooted in social responsibility. DHI's 28% stake in the venture highlights the collaborative efforts to localize Bhutan’s pharmaceutical production, particularly in the manufacturing of high-quality allopathic drugs.
Chandra Obula Reddy, the Chief Executive Officer of ABHL, expresses the company's ambitious vision: “Our aim is to position ABHL as one of the local manufacturers and distributors within Bhutan, and a globally acclaimed pharmaceutical company through development and introduction of a wide portfolio of pharmaceuticals.”
ABHL's mission is historic for Bhutan as it signifies the first local foray into manufacturing, packaging, and distributing allopathic medicines. As marketing officer Nima Dorji emphasizes, this move not only supports Bhutan's healthcare infrastructure but also aims at economic growth by reducing import dependence and elevating Bhutan's standing in the global pharmaceutical arena.
Currently, ABHL offers a diverse product lineup with over 29 varieties of medicines addressing a range of ailments from cancer to gastric disorders. The company is also looking to expand its distribution network to Gelephu and Phuentsholing, ensuring nationwide accessibility.
ABHL's adherence to stringent environmental standards and the Bhutan Food and Drug Authority's regulatory compliance is a testament to its dedication to quality and social responsibility. Embracing Bhutan's Gross National Happiness (GNH) philosophy, ABHL ensures minimal environmental impact while striving for global leadership in healthcare.
As ABHL continues to innovate and lead, it stands as a symbol of Bhutan's commitment to fostering a healthier nation through self-reliance and sustainable growth.
On the auspicious occasion of our beloved King's birthday, the Azista Bhutan team came together for a meaningful initiative - a blood donation camp. We believe in giving back to our community and what better way to celebrate than by contributing to the gift of life. Kudos to our team for embodying the spirit of compassion and unity. Together, we're not just a company; we're a community making a positive impact
We warmly welcomed a 6-member Bhutan Food and Drug Authority team as they visited our ABHL plant for the GMP certificate renewal audit from January 24-26, 2024. We are excited to announce the audit's success, reaffirming our commitment to excellence. To mark this milestone, we captured memorable moments with the BFDA team during their visit and are grateful to the BFDA team for their meticulous evaluation and collaboration. We are delighted that collaboratively, we are paving the way for excellence in the pharmaceutical industry!
Our ABHL plant had the pleasure of hosting a friendly and technical visit from Menjong Sorig Pharmaceuticals Corporation Ltd., a distinguished member of the DHI Group, all the way from Kawang Jangsa, Thimphu. We're thrilled to share glimpses of it. Stay tuned as we gear up to showcase these memorable moments on our official website!
Azista Bhutan’s Audit Close Meet and Greet, concluded with seamlessly merged productivity, sustainability, and enjoyment. In addition to finalizing the audit, participants actively contributed to environmental sustainability by planting saplings, aligning with Azista Bhutan's team fun activities. The event also featured team-building activities, fostering camaraderie among participants. These engaging activities, alongside the audit's meticulous attention to detail, aimed to ensure accuracy, transparency, and compliance. The positive outcomes of the audit lay the groundwork for continuous improvement within Azista Bhutan. Insights gained from both the audit and collaborative activities will shape future organizational strategies, maintaining a focus on excellence, sustainability, and a positive workplace culture.
ABHL(Azista Bhutan Healthcare Limited) participated in a Prestigious Consultation Event We are proud to announce that ABHL(Azista Bhutan Healthcare Limited) recently participated in a significant consultation event. This event was jointly organized by the United Nations Development Programme (UNDP) and the Bhutan Food and Drug Authority (BFDA). Furthermore, it was generously sponsored by the Access Delivery Partnership (ADP). The collaboration between such esteemed organizations underscores the importance of the event and its objectives. As a leading healthcare provider in Bhutan, our participation signifies our commitment to aligning with global standards and best practices. We are grateful for the opportunity to collaborate, share insights, and learn from other industry leaders.
Exciting News! Azista Bhutan is thrilled to introduce our newest product to the market - LANOL 650 Paracetamol Tablets IP 650 MG! We are incredibly proud to share that our dedicated team at ABHL, Bhutan plant, has successfully completed the development and packaging of this fantastic addition to our product range. The LANOL 650 tablets are now ready to provide effective relief and comfort to those in need. With the utmost care and precision, we have crafted LANOL 650 to ensure the highest quality standards, offering you a reliable and trusted solution for your health needs. Whether it's for a headache, fever, or mild pain, LANOL 650 is here to support you through life's little bumps. At Azista Bhutan, we strive to continually enhance our product offerings to better serve our valued customers. Your well-being is our top priority, and we're committed to delivering safe and effective pharmaceutical solutions. We would like to extend our heartfelt gratitude to our amazing team members whose dedication and hard work made this launch possible. This milestone would not have been achieved without their unwavering support. Thank you, our cherished customers and well-wishers, for your continued trust in us. Stay tuned for more exciting updates from Azista Bhutan. Cheers to a healthier tomorrow!
Azista Bhutan, a leading pharmaceutical company, has made its first remarkable milestone by participating in the prestigious Bhutan Thematic Expo 2023. Here, the Bhutan Chamber of Commerce and Industry (BCCI) has launched four indigenous products. It also provided a platform for local entrepreneurs to display their local products. Azista Bhutan has grabbed the opportunity to exhibit its 32 pharmaceutical products, create awareness and understand the local market The expo witnessed the presence of esteemed government representatives who addressed the gathering, highlighting the event's significance. The expo proved a valuable platform for Azista Bhutan to interact with healthcare professionals, industry experts, and potential partners through engaging in discussions and exchanging ideas, nevertheless, Azista Bhutan strengthened its network and fostered meaningful collaborations within the healthcare sector. The expo went for five days till June 26th and one of the key benefits of Azista Bhutan's participation in the expo was its enhanced visibility and brand recognition. Our company's presence at such a prominent event increased its reach and credibility among the medical community and the public. This recognition is expected to drive further growth and solidify Azista Bhutan's position as a trusted pharmaceutical provider in Bhutan. Our participation in the Bhutan Thematic Expo 2023 has given us an inspiration to propel the company towards even greater achievements. With its unwavering commitment to healthcare advancement, Azista Bhutan remains dedicated to improving the lives and well-being of the people it serves.
Azista Bhutan Healthcare Celebrated the birthday of His Majesty the King of Bhutan on the 21st and wished him good health and a wonderful year ahead.
Mr. Obula Reddy, the Chief Executive Officer of Azista Bhutan Healthcare Ltd officially met the Indian Deputy Chief of Mission Mr. Niteen Shubash Yeola on Monday, i.e., 13th of February 2023 at Indian Embassy in Thimphu, Bhutan
Azista Bhutan Healthcare Ltd. (ABHL) donates two iScan Breast devices manufactured by its sister company in India to Jigme Dorji Wangchuk National Referral Hospital for breast cancer screening and early detection.
On this auspicious day, Azista Bhutan Healthcare Limited (ABHL) delivers two more products: FX24 120 mg -Fexofenadine Hydrochloride and EZEE 500 Azithromycin 500mg, in addition to the RHICET -Levocetirizine Hydrochloride and RHICET M - Montelukast 10 mg +Levocetirizine Hydrochloride 5mg that was delivered last month. In the preceding month, Lanol 500-Paracetamol was released. Today, ABHL has five medicines in the market. Many more products are already being developed and should be available to the customers soon. ABHL's goal is to ensure that Bhutanese citizens have access to high-quality, affordable, and timely medicines.
Azista Bhutan Healthcare Ltd. (ABHL) is FDI pharmaceutical company, a joint venture between Azista Industries Pvt. Ltd., Hyderabad, India and Druk Holding and Investments Ltd. (DHI), Bhutan with 72% and 28% shareholding, respectively. ABHL is located at Motanga Industrial Park, Samdrup Jongkhar, spread across 6.757 acres. ABHL is the first allopathic pharmaceutical manufacturer, packager, and distributor in Bhutan with the production capacity of General block 43.8 million capsules/tablets and Oncology block 16.8 million capsules/tablets per month. The Drug Regulatory Authority, RGoB, has certified ABHL for good manufacturing practice (GMP). Currently, the company has Technical Authorization to manufacture 213 goods (136 general medicines and 77 cancer drugs) across 17 distinct therapies. The oncology block is ready for production as well as packaging, while the general block is only ready for packaging. ABHL is currently working with distributors and retailers across the country, and has already received purchase orders for a few products from distributors. Oncology items will be manufactured in the coming days in response to demand from both domestic and international markets.
ABHL is donating 121,000 paracetamol 500mg (Brand:Lanol) tablets to the Ministry of Health, RGoB, which is the first product packaged at ABHL.
Mr. M Srinivasa Reddy, Director of our Azista Bhutan Healthcare Limited, inaugurated the new plant in Bhutan on Sunday, i.e., 9th of February 2020. The plant constructed at Motanga Industrial Park, Samdrup Jongkhar, in Bhutan. He launched the website www.azistabhutanhealthcare.com of our organization as part of the inaugural event. He also took part in the machine commissioning of our new plant. The inauguration happened amidst other leaders and employees of our Azista Bhutan Healthcare, the company which is a joint venture of Azista Industries Pvt. Ltd., Hyderabad and Druk Holding and Investments Ltd., RGoB, Bhutan.
Place: Conference Hall of HHCL-Unit-II, Guwahati, India. Board of Directors attended: Dasho Tharchin Lhendup – Chairman Mr. M. Srinivas Reddy – Managing Director Mr. Sherab Namgay – Director Mr. P.B.C. Obula Reddy – CEO
Copyright © All Rights Reserved by Azista Bhutan Healthcare Limited.
